Skip to content
Clinical Trials – home
SlovakiaBack to Slovakia

Clinical trials in Ilava – page 16

209 clinical trials in Ilava, Slovakia. Every trial is listed in the EU Clinical Trials Register and updated daily.

SlovakiaOur site in SlovakiaKlinickeSkusky.sk(opens in a new tab)
Ilava at a glance
209
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

209 trials in Ilava

Open in trial search

Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with BRAF V600E/K Mutation-Positive Melanoma After Anti-PD-1 Therapy

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib
  • Sponsor:Pfizer Inc.

Study of talazoparib and enzalutamide combination in men with DDR gene mutated metastatic castration-sensitive prostate cancer

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Cardiac failure

Not recruiting

Study on Balcinrenone and Dapagliflozin for Patients with Heart Failure and Kidney Problems

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Balcinrenone
  • Sponsor:AstraZeneca AB

Study of Capivasertib and Abiraterone for Patients with Metastatic Hormone-Sensitive Prostate Cancer with PTEN Deficiency

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:AstraZeneca AB

Study on the Effectiveness and Safety of Cenobamate for Patients Aged 12 and Older with Primary Generalized Tonic-Clonic Seizures

Investigational
Countries:SlovakiaSlovakia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cenobamate
  • Sponsor:Sk Life Science Inc.

Study of Batoclimab for Treating Patients with Active Thyroid Eye Disease

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Batoclimab
  • Sponsor:Immunovant Sciences GmbH

Multiple sclerosis

Not recruiting

Study on Long-Term Safety and Efficacy of Ocrelizumab for Patients with Multiple Sclerosis

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Asthma

Not recruiting

Study on the Long-term Effects of Dupilumab in Preventing Lung Function Decline in Adults with Uncontrolled Moderate to Severe Asthma

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Dry eye+1

Not recruiting

Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Ianalumab
  • Sponsor:Novartis Pharma AG

Psoriatic arthropathy

Not recruiting

Study on Long-Term Safety and Effectiveness of Bimekizumab for Adults with Active Psoriatic Arthritis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bimekizumab
  • Sponsor:UCB Biopharma

Study on Batoclimab for Patients with Thyroid Eye Disease

InvestigationalNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Batoclimab
  • Sponsor:Immunovant Sciences GmbH

Study of BAT3306 or pembrolizumab with chemotherapy (carboplatin and pemetrexed) in patients with stage IV non-squamous non-small cell lung cancer

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bio-Thera Solutions Ltd.

Other cities in Slovakia

The busiest research cities in the country

All 88 cities in Slovakia

Clinical research in Ilava

What the registry says about research in the country

01 Cardiovascular Diseases

The clinical trial activity in Ilava includes research in cardiovascular diseases, with a focus on improving protection against major heart-related events and related complications. These studies are exploring new ways to reduce risk in people living with established or high-risk heart conditions.

  • Atherosclerotic cardiovascular disease
  • Established cardiovascular disease
  • High cardiovascular risk
  • Hypertension

The goal is to evaluate whether new treatments can better prevent serious outcomes such as heart attack, stroke, heart failure, and cardiovascular death.

02 Nutritional and Metabolic Diseases

Another key area in this research landscape is nutritional and metabolic diseases, especially conditions linked to excess weight and metabolic risk. The trials are looking at therapies that may support weight reduction while also improving broader health outcomes.

  • Obesity
  • Overweight
  • Chronic kidney disease

In Ilava, this work is aimed at understanding whether newer treatments can help lower the burden of obesity-related complications and support kidney health at the same time.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.